Mechanism of Action of Tranexamic Acid
Tranexamic acid (TXA) is an antifibrinolytic agent that works by blocking lysine-binding sites on plasminogen and plasmin, thereby preventing the breakdown of fibrin clots and stabilizing hemostasis. 1
Core Pharmacologic Mechanism
TXA is a synthetic lysine amino acid derivative that exerts its primary effect through competitive inhibition at multiple binding sites within the plasminogen molecule 1. The drug's mechanism operates through the following pathway:
Primary Antifibrinolytic Action
- Plasminogen contains 4-5 low-affinity lysine binding sites (Kd = 750 μmol/L) and 1 high-affinity site (Kd = 1.1 μmol/L) 1
- The high-affinity lysine site is critical for plasminogen's binding to fibrin during clot formation
- When TXA saturates these binding sites, it displaces plasminogen from the fibrin surface, preventing its conversion to plasmin 1
- Even if plasmin forms through conformational changes in plasminogen, TXA prevents it from binding to and degrading the fibrin matrix 1
Clinical Pharmacodynamics
The antifibrinolytic effect manifests as:
- Preservation and stabilization of fibrin's matrix structure by preventing plasmin-mediated dissolution 1
- Prolongation of thrombin time at concentrations of 1-10 mg/mL 1
- Antifibrinolytic concentrations persist in tissues for approximately 17 hours and in serum for 7-8 hours 1
- No effect on platelet count, coagulation time, or coagulation factors at therapeutic concentrations up to 10 mg/mL 1
Beyond Classical Fibrinolysis
Recent evidence reveals TXA has cellular effects beyond simple antifibrinolytic activity 2:
- Inhibition of endothelial sheddase activation, which helps preserve the endothelial glycocalyx and vascular barrier function 3
- Modulation of leukocyte-associated plasminogen activation, which may reduce thrombin generation in whole blood environments 4
- Anti-inflammatory effects through interference with plasminogen/plasmin-mediated inflammatory pathways in keratinocytes and macrophages 5
Important Clinical Context
The mechanism's effectiveness is highly time-dependent. Studies demonstrate that TXA must be administered early (within 60-90 minutes of injury) to prevent glycocalyx degradation and optimize hemostatic benefit 3, 6. Late administration loses protective effects as the pathologic cascade has already progressed beyond the point where plasminogen inhibition provides benefit.
Pharmacokinetic Considerations
- >95% renal excretion as unchanged drug with renal clearance equal to plasma clearance (110-116 mL/min) 1
- Terminal elimination half-life of approximately 2 hours 1
- Minimal protein binding (3%) primarily to plasminogen, not albumin 1
- Dose adjustment required in renal impairment as drug accumulation occurs with declining kidney function 1